Let's Talk About Risk: FDA Plans Meeting On Postmarket Risk Management
This article was originally published in The Silver Sheet
Executive Summary
Online-Only Content >>> FDA will hold an interactive workshop on April 21 to discuss the "clinical considerations of risk in the postmarket environment." The meeting will build on a process launched last fall when representatives from industry and FDA met to establish draft principles for managing unanticipated risks for marketed devices.